Health-care companies slipped as vaccine makers remained under pressure. Shares of Novavax plunged by 8%, compounding losses in the wake of the vaccine developer's earnings report. Rival Moderna lost ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All ...

Yes, you can get your flu and COVID-19 shots at the same time. Don’t call them boosters — they’re not just another dose of ...

Wall Street's three major indexes closed lower on Tuesday as investors booked some profits from a post-election rally and ...

Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to 19,281.40 ...

Biotech firm Novavax dropped after cutting its annual revenue forecast due to lower-than-expected sales of its COVID-19 ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, is proud to announce an exciting new partnership with the Los Angeles Rams aimed at "Protecting the Rams House" ...